Ba. Mccullough et al., Genotype spectrum of ornithine transcarbamylase deficiency: Correlation with the clinical and biochemical phenotype, AM J MED G, 93(4), 2000, pp. 313-319
Ornithine transcarbamylase (OTC) deficiency, a partially dominant X-linked
disorder, is the most common inherited defect of the urea cycle. Previous r
eports suggested a variable phenotypic spectrum, and several studies docume
nted different "private" mutations in the OTC genes of patients. Our labora
tory identified disease-causing mutations in 157 families with OTC deficien
cy, 100 of which came to medical attention through a hemizygous propositus
and in 57 the index case was a heterozygous female. We correlated the genot
ype with age of onset, liver OTC activity, incorporation of nitrogen into u
rea, and peak plasma ammonia levels. The "neonatal onset" group has a homog
enous clinical and biochemical phenotype, whereas the "late onset" group sh
ows an extremely wide phenotype; 60% of the mutations are associated exclus
ively with acute neonatal hyperammonemic coma. The remaining mutations caus
ed a nonuniform phenotype ranging from severe disease to no symptoms; 31% o
f the mutations in the OTC gene occur in CpG; dinucleotides (methylation-me
diated deamination), and none of them accounted for more than 4% of the tot
al. Eighty-six percent of the mutations represented single-base substitutio
ns and 68% of the substitutions were transitions. G-to-A and C-to-T transit
ions were the most frequent substitutions (34 and 21%, respectively) wherea
s C-to-A, A-to-C, C-to-G;, and T-to-A transversions were the least common (
1.5-3%). Twenty percent of propositi and 77% of propositae carried new muta
tions. Forty percent of female germinal mutations were in CpG: dinucleotide
s whereas this number appears much smaller in male germinal mutations. Thes
e data allow classification of patients with OTC deficiency into at least t
wo groups who have discordant disease course and prognoses. In addition, th
ey improve our understanding on the origin of mutations in the OTC gene and
allow better counseling of affected families. (C) 2000 Wiley-Liss, Inc.